BRPI0607649B8 - uso de uma formulação subcutânea ou intramuscular compreendendo uma quantidade eficaz de tmc278 e um veículo - Google Patents
uso de uma formulação subcutânea ou intramuscular compreendendo uma quantidade eficaz de tmc278 e um veículoInfo
- Publication number
- BRPI0607649B8 BRPI0607649B8 BRPI0607649A BRPI0607649A BRPI0607649B8 BR PI0607649 B8 BRPI0607649 B8 BR PI0607649B8 BR PI0607649 A BRPI0607649 A BR PI0607649A BR PI0607649 A BRPI0607649 A BR PI0607649A BR PI0607649 B8 BRPI0607649 B8 BR PI0607649B8
- Authority
- BR
- Brazil
- Prior art keywords
- tmc278
- subcutaneous
- vehicle
- effective amount
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05102616.9 | 2005-04-04 | ||
EP05102616 | 2005-04-04 | ||
PCT/EP2006/061303 WO2006106103A2 (en) | 2005-04-04 | 2006-04-04 | Prevention of hiv- infection with tmc278 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0607649A2 BRPI0607649A2 (pt) | 2009-09-22 |
BRPI0607649B1 BRPI0607649B1 (pt) | 2019-08-06 |
BRPI0607649B8 true BRPI0607649B8 (pt) | 2021-05-25 |
Family
ID=34939113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607649A BRPI0607649B8 (pt) | 2005-04-04 | 2006-04-04 | uso de uma formulação subcutânea ou intramuscular compreendendo uma quantidade eficaz de tmc278 e um veículo |
Country Status (29)
Country | Link |
---|---|
US (6) | US20080194601A1 (pt) |
EP (1) | EP1881848B1 (pt) |
JP (2) | JP5632579B2 (pt) |
KR (1) | KR101360851B1 (pt) |
CN (2) | CN101155599A (pt) |
AP (1) | AP2617A (pt) |
AR (1) | AR053571A1 (pt) |
AU (1) | AU2006231585B2 (pt) |
BR (1) | BRPI0607649B8 (pt) |
CA (1) | CA2602231C (pt) |
CY (1) | CY1113950T1 (pt) |
DK (1) | DK1881848T3 (pt) |
EA (1) | EA011420B1 (pt) |
ES (1) | ES2402864T3 (pt) |
HK (2) | HK1117039A1 (pt) |
HR (1) | HRP20130296T1 (pt) |
IL (1) | IL184744A (pt) |
ME (1) | ME01517B (pt) |
MX (1) | MX2007012277A (pt) |
MY (1) | MY150091A (pt) |
NZ (1) | NZ556659A (pt) |
PL (1) | PL1881848T3 (pt) |
PT (1) | PT1881848E (pt) |
RS (1) | RS52724B (pt) |
SI (1) | SI1881848T1 (pt) |
TW (2) | TW201414495A (pt) |
UA (1) | UA90124C2 (pt) |
WO (1) | WO2006106103A2 (pt) |
ZA (1) | ZA200708454B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
TW201414495A (zh) * | 2005-04-04 | 2014-04-16 | Tibotec Pharm Ltd | Hiv-感染之預防 |
PL1981506T6 (pl) | 2006-01-20 | 2021-07-12 | Janssen Sciences Ireland Uc | Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278 |
CA2654115C (en) * | 2006-06-23 | 2015-12-22 | Tibotec Pharmaceuticals Ltd. | Aqueous suspensions of tmc278 |
CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
EP2381961B1 (en) * | 2008-12-24 | 2016-09-14 | Janssen Sciences Ireland UC | Implantable devices for treating hiv |
SG181759A1 (en) | 2009-12-21 | 2012-07-30 | Janssen R & D Ireland | Degradable removable implant for the sustained release of an active compound |
DE102011082871A1 (de) * | 2011-09-16 | 2013-03-21 | Florian, Prof. Dr. Lang | Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen |
JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
WO2014093941A1 (en) | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Pharmaceutical compositions |
CN106999425A (zh) * | 2014-09-26 | 2017-08-01 | 葛兰素史克知识产权第二有限公司 | 长效药物组合物 |
WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06316524A (ja) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
PL366089A1 (en) | 2000-03-30 | 2005-01-24 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
US20040115268A1 (en) * | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
CA2505130C (en) | 2002-11-08 | 2009-10-06 | Glaxo Group Limited | Pharmaceutical compositions |
AU2003282883B2 (en) | 2002-11-18 | 2008-12-04 | Polaris Group | Methods for inhibiting viral replication in vivo |
MXPA05008364A (es) | 2003-02-07 | 2005-11-04 | Janssen Pharmaceutica Nv | Derivados de pirimidina para la prevencion de una infeccion por vih. |
US20040180893A1 (en) | 2003-02-21 | 2004-09-16 | Balzarini Jan Maria Rene | Identification of compounds that inhibit replication of human immunodeficiency virus |
TW201414495A (zh) * | 2005-04-04 | 2014-04-16 | Tibotec Pharm Ltd | Hiv-感染之預防 |
PL1981506T6 (pl) * | 2006-01-20 | 2021-07-12 | Janssen Sciences Ireland Uc | Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278 |
CA2654115C (en) * | 2006-06-23 | 2015-12-22 | Tibotec Pharmaceuticals Ltd. | Aqueous suspensions of tmc278 |
-
2006
- 2006-04-03 TW TW102132228A patent/TW201414495A/zh unknown
- 2006-04-03 TW TW095111848A patent/TWI457136B/zh active
- 2006-04-04 RS RS20130136A patent/RS52724B/en unknown
- 2006-04-04 ME MEP-2013-30A patent/ME01517B/me unknown
- 2006-04-04 AP AP2007004178A patent/AP2617A/xx active
- 2006-04-04 JP JP2008504756A patent/JP5632579B2/ja active Active
- 2006-04-04 CN CNA2006800114294A patent/CN101155599A/zh active Pending
- 2006-04-04 CA CA2602231A patent/CA2602231C/en active Active
- 2006-04-04 CN CN201410057428.XA patent/CN103860560A/zh active Pending
- 2006-04-04 KR KR1020077019959A patent/KR101360851B1/ko active IP Right Grant
- 2006-04-04 WO PCT/EP2006/061303 patent/WO2006106103A2/en active Application Filing
- 2006-04-04 PT PT67255398T patent/PT1881848E/pt unknown
- 2006-04-04 BR BRPI0607649A patent/BRPI0607649B8/pt active IP Right Grant
- 2006-04-04 PL PL06725539T patent/PL1881848T3/pl unknown
- 2006-04-04 EP EP06725539A patent/EP1881848B1/en active Active
- 2006-04-04 MY MYPI20061522A patent/MY150091A/en unknown
- 2006-04-04 US US11/910,034 patent/US20080194601A1/en not_active Abandoned
- 2006-04-04 NZ NZ556659A patent/NZ556659A/en unknown
- 2006-04-04 AU AU2006231585A patent/AU2006231585B2/en active Active
- 2006-04-04 SI SI200631560T patent/SI1881848T1/sl unknown
- 2006-04-04 MX MX2007012277A patent/MX2007012277A/es active IP Right Grant
- 2006-04-04 DK DK06725539.8T patent/DK1881848T3/da active
- 2006-04-04 EA EA200702169A patent/EA011420B1/ru unknown
- 2006-04-04 AR ARP060101333A patent/AR053571A1/es not_active Application Discontinuation
- 2006-04-04 UA UAA200708560A patent/UA90124C2/ru unknown
- 2006-04-04 ES ES06725539T patent/ES2402864T3/es active Active
-
2007
- 2007-07-19 IL IL184744A patent/IL184744A/en active IP Right Grant
- 2007-10-03 ZA ZA200708454A patent/ZA200708454B/xx unknown
-
2008
- 2008-06-27 HK HK08107189.8A patent/HK1117039A1/xx unknown
-
2010
- 2010-12-06 US US12/961,305 patent/US20110077261A1/en not_active Abandoned
-
2012
- 2012-12-28 JP JP2012287041A patent/JP2013079275A/ja active Pending
-
2013
- 2013-03-29 HR HRP20130296TT patent/HRP20130296T1/hr unknown
- 2013-04-16 CY CY20131100311T patent/CY1113950T1/el unknown
-
2014
- 2014-12-16 HK HK14112581.4A patent/HK1198936A1/xx unknown
-
2016
- 2016-02-05 US US15/017,168 patent/US20160151276A1/en not_active Abandoned
- 2016-06-13 US US15/180,391 patent/US10765674B2/en active Active
-
2020
- 2020-09-02 US US17/010,578 patent/US20200397783A1/en not_active Abandoned
-
2021
- 2021-09-17 US US17/478,029 patent/US20220071997A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607649B8 (pt) | uso de uma formulação subcutânea ou intramuscular compreendendo uma quantidade eficaz de tmc278 e um veículo | |
CY1120564T1 (el) | Υδατικα εναιωρηματα tmc278 | |
CY1120389T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη | |
BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
BRPI0607728A2 (pt) | complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado | |
BR112015004501A2 (pt) | derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo | |
BRPI0611800A2 (pt) | formulaÇço estÁvel de anticorpo | |
BR112015018161A2 (pt) | Conjugado de oligômeros antisense de lna, composição farmacêutica e uso de um conjugado de oligômeros antisense de lna | |
BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
CY1113003T1 (el) | Ευσταθη παρασκευασματα laquinimod | |
CY1112335T1 (el) | Παραδοση παρατεταμενης αποδεσμευσης αλατων αμφεταμινης | |
BRPI0509927A (pt) | composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina | |
BRPI0809366A8 (pt) | polipeptídeos interligados | |
BRPI0606112B8 (pt) | 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos | |
CL2008000751A1 (es) | Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c. | |
BRPI0415779A (pt) | tratamento de doenças proliferativas usando um oligÈmero antisenso iap e um agente quimioterápico | |
BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
ATE454905T1 (de) | Stabile injizierbare diclofenac- zubereitungen | |
BRPI0410857A (pt) | método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica | |
DK1868581T3 (da) | Farmaceutiske sammensætninger med forbedrede opløsningsprofiler til dårligt opløselige lægemidler | |
TW200640519A (en) | Microprojection arrays with improved biocompatibility | |
CL2009001089A1 (es) | Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
UY31146A1 (es) | Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene | |
BRPI0920258A2 (pt) | composição, processo para fabricar composição, processo para fabricar um polímero de pelo menos um éster acrílico, artigo ou parte de artigo, e, uso da composição | |
ATE450273T1 (de) | Proliferationshemmendes arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: TIBOTEC PHARMACEUTICALS (IE) |
|
B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |